DOCSLIB.ORG

Family Conference Dec

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Family Conference Dec 33RD ANNUAL NATIONAL MPS SOCIETY FAMILY CONFERENCE DEC. 19–21, 2019 • ORLANDO, FL #mpsfamily2019 MISSION STATEMENT The National MPS Society exists to cure, support and advocate for MPS and ML. Contents MPS and ML Chair Letter 1 Mucopolysaccharidoses (MPS) and Mucolipidosis (ML) are genetic lysosomal storage diseases (LSD) caused by the body’s inability to Board of Directors/Staff 2 produce specific enzymes. General Information 3 MPS I MPS IV Hotel Layout 5 MPS I H Hurler MPS IV A Morquio A Schedule 6 MPS I S Scheie Enzyme / Galactose 6-sulfatase MPS IV B Morquio B Speakers 10 MPS I H-S Hurler-Scheie Enzyme / a-L-Iduronidase Enzyme / B-Galactosidase Attendees 30 MPS VI Thank You to Our Sponsors 36 MPS II MPS II Hunter MPS VI Maroteaux-Lamy Notes 38 Enzyme / Iduronate sulfatase Enzyme / (arylsulfatase B) N-Acetylgalac-tosamine 4-sulfatase MPS Jingle Bell Run/Walk 41 MPS III Upcoming Events 42 MPS VII MPS III A Sanfilippo A Enzyme / Heparan N-sulfatase MPS VII Sly Enzyme / B-Glucuronidase MPS III B Sanfilippo B Enzyme / a-N- Acetylglucosaminidase MPS IX MPS III C Sanfilippo C Enzyme / Hyaluronidase Enzyme / Acetyl CoA: a-glycosaminide acetyltransferase ML II/III MPS III D Sanfilippo D Enzyme / N-Acetylglucosamine ML II I-Cell 6-sulfatase ML III Psuedo-Hurler polydystrophy Enzyme / N-acetylglucosamine-1- phosphotransferase Chair Letter I am so excited to be at the National MPS Society’s 33rd Annual Family Conference at the most magical place on earth! Our family conference has a special place in my heart. I dearly treasure the time I spend with all of you and the entire MPS and ML community each year. Eight years ago, I attended my first family conference, just a few weeks after my son Jack was diagnosed with MPS II. The support, encouragement and education I received at that conference changed our lives forever. While I was overwhelmed, I was also filled with hope and extreme gratitude for this amazing community and all the support it provides. Endless opportunities abound at this conference, and I encourage you to take full advantage of your time here. This is the time to share your stories, ask questions, learn about treatment options and emerging research, and spend time cherishing old friends and making new ones. All of our stories illustrate the different paths that have brought us here, but what joins us together as a community is a special and unique bond—the MPS journey. I look forward to getting to know each of you, hearing your stories, and sharing all the great news on emerging technology, research and the amazing endeavors of the National MPS Society. Together, we will continue to build this community and lead the way to a better future for all those impacted by these devastating diseases. In the words of Walt Disney, “If you can dream it, you can do it.” May the magic of Disney inspire and uplift you during our 2019 conference! Lisa P. Todd Chairman, National MPS Society Thank you to Grey Chapin, B.L.A.I.R. Connection, who with the support of her network generously donated all of the family gift bags. Thank you, Grey! Thank you to the 33rd Annual Family Conference committee members: Amy Holland Lynn Hopkins Kris Klenke Amber Mongan Conference Registration and Coordinators: Katelyn Blackman Leslie Urdaneta #mpsfamily2019 – 1 – Board of Directors Lisa Todd, Chairman Kristine Klenke STAFF 11111 Jordan NE 7604 Sherry Creek Road Albuquerque, NM 87122 Worden, IL 62097 Terri Klein, President and CEO Home: 505.797.3603 Home: 618.888.2204 [email protected] Lisa Cell: 505.263.9593 Cell: 618.718.3295 [email protected] [email protected] Brian Buechler, Director of Development Steve Holland, Vice Chairman Jason Madison [email protected] Amy Holland 236½ North 11th St. 4908 Barbara Road Allentown, PA 18194 Leslie Urdaneta, Family Program River Oaks, TX 76114 Cell: 718.925.5860 Coordinator Steve Cell: 817.874.7461 [email protected] [email protected] Amy Cell: 817.874.7460 [email protected] Amber Mongan Katelyn Blackman, Development and [email protected] 5330 Saratoga St. Program Coordinator Eugene, OR 97405 [email protected] Lynn Hopkins, Treasurer 509.475.6453 Scott Hopkins [email protected] Rebecca Luchenbill, Administrative 6210 Parima St. Specialist Long Beach, CA 90803 Austin Noll [email protected] Lynn Cell: 310.210.9177 19715 North Shore Drive [email protected] Spring Lake, MI 49456 Coreen Gray, Family Support Lead [email protected] Cell: 408.438.8519 [email protected] [email protected] Christine Tippett, Secretary Angela Guajardo, Controller 6 Glenridge Drive Sheri Wise [email protected] Littleton, CO 80123 1941 Lariet Lane 303.408.2844 Del City, OK 73115 [email protected] Cell: 405.229.1133 [email protected] Stephanie Bozarth Austin Bozarth 1220 Daviswood Drive McLean, VA 22102 Home: 703.256.1980 Stephanie Cell: 202.257.7808 Austin Cell: 703.608.3999 [email protected] [email protected] SCIENTIFIC ADVISORY BOARD Matthew Ellinwood, DVM, PhD, chair John Hopwood, PhD Calogera Simonaro, PhD Alessandra D’Azzo, PhD William Mackenzie, MD William Sly, MD Lorne A. Clarke, MD Joseph Muenzer, MD, PhD Richard Steet, PhD Robert Desnick. MD PhD Elizabeth Neufeld, PhD Charles H. Vite, DVM, PhD Patricia Dickson, MD Matthew Pendleton, PhD Steven Walkley, DVM, PhD Julie Eisengart, PhD Lynda Polgreen, MD, MS Chester Whitley, PhD, MD Paul Harmatz, MD Kathy Ponder, MD John H. Wolfe, VMD, PhD Mark Haskins, VMD, PhD Mark Sands, PhD Klane White, MD, MSc Kim Hemsley, PhD Edward Schuchman, PhD David Wenger, PhD #mpsfamily2019 – 2 – General Information NAME BADGE POLICY SCHEDULE Attendees must wear their registration name badge at all Please note that the included schedule is subject to change. times to gain access to meetings, sessions and meals. CONTACT INFORMATION NATIONAL MPS SOCIETY CHILD CARE POLICY National MPS Society The National MPS Society offers complimentary child care, Physical: 1007 Slater Road, Suite 220, Durham, NC 27703 Camp Courage, at our conference. This enables parents Mailing: P.O. Box 14686, Durham, NC 27709-4686 and caregivers to attend and participate in the conference t: 877.MPS.1001 • p: 919.806.0101 • f: 919.806.2055 presentations and concurrent sessions, confident that their email: [email protected] • web: www.mpssociety.org children are being cared for in a safe environment. Camp Courage is offered for children age 2 and older. All children, MEDICAL FACILITIES/SERVICES including children younger than 2, are welcome to join their Hospital/Emergency Room parents in the educational sessions as needed. Orlando Health Orlando Regional Medical Center We are excited to partner with KiddieCorp again this year. 52 W. Underwood St. Parents or caregivers must check in and check out each Orlando, FL 32806 child every time the child enters and leaves child care. www.orlandohealth.com Photo ID is required. One parent or caregiver must always 321.841.5111 remain in the meeting session rooms while their child is in child care. KiddieCorp must be able to reach the parent/ caregiver at all times. Children will receive wristbands indicating whether or not they can have snacks of crackers SOCIAL MEDIA and juice. Volunteers will not dispense prescription or over- Stay on top of things at the conference by following the-counter medication to children, or provide other food or @mpssociety on Twitter and Instagram and liking us on feedings. In addition, volunteers will not change diapers. Facebook. Join the conference conversation by using our The child care supervisor, the National MPS Society’s conference hashtag #mpsfamily2019. board of directors and staff are authorized to restrict a child from child care if it is determined that the child cannot be adequately cared for or if they are a danger to themselves or to others. Unfortunately, we are unable to provide one- on-one care, but we welcome a parent or caregiver who chooses to stay with the child while in child care. Camp Courage Schedule Thursday, December 19 12:30 pm Camp Courage opens 4:40 pm Camp Courage closes 6:15 pm Camp Courage opens 9:40 pm Camp Courage closes Friday, December 20 11:45 am Camp Courage opens 5:35 pm Camp Courage closes Each child attending must be registered for the conference and for Camp Courage. A parent or caregiver must be registered for the conference and remain in the meeting sessions for the duration of Camp Courage. #mpsfamily2019 – 3 – General Information WORSHIP SERVICES Islam Islamic Center of Orlando Jama Masjid Assemblies of God 11543 Ruby Lake Road Faith Assembly of God www.icorlando.org 9307 Curry Ford Road 407.238.2700 www.faithassembly.org 407.275.8790 Jehovah’s Witness Kingdom Hall, Clear Lake Baptist 1701 S. Lee Ave. First Baptist Orlando www.jw.org 3000 South John Young Pkwy. 407.425.1125 www.firstorlando.com 407.425.2555 Jewish Southwest Orlando Jewish Congregation (Conservative) Buddhist 11200 S. Apopka-Vineland Road Vajrapani Kadampa Buddhist Center www.sojc.org 813 Montana St. 407.239.5444 www.meditationinorlando.org 407.896.3998 Congregation Ahavas Yisrael-Orthodox 708 Lake Howell Road Catholic 407.644.2500 Holy Family Catholic Church of Orlando 5125 S. Apopka-Vineland Road Congregation of Reform Judaism www.holyfamilyorlando.com 928 Malone Drive 407.876.2211 www.crjorlando.org 407.645.0444 Christian Science First Church of Christ, Scientist Lutheran 915 North Fern Creek Ave. Trinity Evangelical Lutheran Church www.christianscienceorlando.com 123 E. Livingston St. 407.896.0770 www.church.trinitydowntown.com 407.488.1919 Church of Jesus Christ of Latter-day Saints Orlando Florida Temple Methodist 9000 Windy Ridge Road First United Methodist Church of Orlando www.churchofjesuschrist.org/temples/details/orlando- 142 E.
Load more

Recommended publications
  • SANGAMO THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 SANGAMO THERAPEUTICS, INC. (exact name of registrant as specified in its charter) Delaware 68-0359556 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 501 Canal Blvd Richmond, California 94804 (Address of principal executive offices) (510) 970-6000 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
    [Show full text]
  • Medicines in Development -- Cell Therapy and Gene Therapy
    Medicines in Development -- Cell Therapy and Gene Therapy Alzheimer's Disease Drug Name Sponsor Indication Development Phase allogeneic mesenchymal Stemedica Cell Technologies Alzheimer's disease Phase II stem cell therapy (itMSCs) San Diego, CA www.stemedica.com AstroStem Nature Cell Alzheimer's disease Phase I/II stem cell therapy Seoul, South Korea www.stemcellbio.com Arthritis/Musculoskeletal Disorders Drug Name Sponsor Indication Development Phase AdipoCell™ U.S. Stem Cell intervertebral disc degeneration Phase II adipose-derived autologous Sunrise, FL www.us-stemcell.com stem cell therapy CybroCell™ SpinalCyte intervertebral disc degeneration Phase I/II human dermal fibroblast-based Houston, TX www.spinalcyte.com cell therapy ECCO-50 Cytori Therapeutics osteoarthritis of the knee Phase II completed (adipose-derived autologous stem San Diego, CA www.cytori.com and regenerative cell therapy) Medicines in Development: Cell Therapy and Gene Therapy ǀ 2018 1 Arthritis/Musculoskeletal Disorders Drug Name Sponsor Indication Development Phase IDCT DiscGenics lumbar degenerative disc disease Phase I/II (allogeneic injectable discogenic Salt Lake City, UT www.discgenics.com cell therapy) JointStem Nature Cell osteoarthritis of the knee Phase II mesenchymal stem cell therapy Seoul, South Korea www.stemcellbio.com mesenchymal stem cell therapy Medipost osteoarthritis Phase I/II completed Seoul, South Korea www.medipost.com PLX-PAD (emiplacel) Pluristem Therapeutics muscle injury following arthroplasty Phase III (human placental stromal cell
    [Show full text]
  • Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
    Sangamo Therapeutics Logo Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer February 22, 2018 -- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology -- SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. Kite will use Sangamo's ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients. Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo's technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones. Sangamo would also receive tiered royalties on sales of potential future products resulting from the collaboration. Kite will be responsible for all development, manufacturing and commercialization of products under the collaboration, and will be responsible for agreed upon expenses incurred by Sangamo. "This collaboration between Kite and Sangamo brings together two leading platforms to develop best-in-class cell therapies in oncology," said Sandy Macrae, President and Chief Executive Officer of Sangamo.
    [Show full text]
  • Sangamo Therapeutics Reports First Quarter 2019 Financial Results
    Sangamo Therapeutics Logo Sangamo Therapeutics Reports First Quarter 2019 Financial Results May 8, 2019 Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif., May 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights. "With recent encouraging clinical data in hemophilia A gene therapy and ex vivo gene-edited cell therapy for beta thalassemia, we are moving closer to achieving our vision for Sangamo as an integrated genomic medicine company," said Sandy Macrae, CEO of Sangamo. "Our capabilities in gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and gene regulation enable us to address genetic diseases with appropriate technologies. We are investing in a diverse pipeline of products where we believe this suite of proprietary technologies is clinically relevant, where the underlying biology is well-characterized, and where there is a defined high unmet medical need." Recent Highlights Clinical In partnership with Pfizer, announced phase 1/2 interim data for SB-525, a gene therapy candidate for the treatment of adults with hemophilia A, demonstrating dose-dependent increases in Factor VIII (FVIII) activity in eight patients, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels Initiated dose expansion of the 3e13 vg/kg dose cohort for the SB-525 hemophilia A program, based on Safety Monitoring Committee recommendations Announced early data
    [Show full text]
  • Post-Event Summary
    VIRTUAL BIOMANUFACTURING WORLD SUMMIT 20 NOVEMBER 16-17, 2020 POST-EVENT SUMMARY EVENT SITE EPTHOUGHTLEADERS.COM EP_BIOMAN EXECUTIVE PLATFORMS HIGHLIGHTS 200+ Attendees 99% 85% Director-Level have personal budgetary 120+ and Above responsibilities over $5M GLOBAL ORGANIZATIONS 71% have an annual company revenue over $1B Keynotes, case studies, “Excellent ‘virtual’ roundtable discussions, conference with a broad 30+ workshops and more range of presentations and great information exchange on technologies transforming the biopharmaceutical industry.” 20+ Head, Global Biologics Solution Operating Unit providers Days of virtual networking, learning and 2 sharing ideas BIOMANWORLD.COM BMWS20 2 SPEAKERS Here are just a few of our speakers: Juan Andres Patrick Yang Chief Technical Operations Chairman at Acepodia and Quality Officer & Founding Board Director at Sana Biotechnology Lou Schmukler Michael Kamarck EVP and President, Global Product Chief Technology Officer Development & Supply Alison Moore Pam Cheng Chief Technology Officer EVP, President Global Operations & IT Jerry Cacia Derek Adams SVP, Head Global Technical Development Chief Technology and Manufacturing Officer John Pinion Brendan O’Callaghan EVP Translational Sciences, SVP & Global Head Chief Quality Operations Officer of Specialty Care IA Arleen Paulino Jens Vogel SVP Global Manufacturing SVP & Global Head of Biotech Charlene Banard Craig Kennedy Global Head of Technical Operations SVP Global Supply Chain Management for Cell & Gene Therapy BIOMANWORLD.COM BMWS20 3 ATTENDEES A2 Biotherapeutics Sr. Director, Tech Ops Bristol Myers Squibb Sr. Director Acadia Director QA Bristol Myers Squibb Sr. Research Associate Acceleron Pharma Inc VP, Quality Bristol Myers Squibb Director, Cell Culture Eng. CoE (Cell Therapy) Acepodia & Sana Biotechnology Chairman & Founding Board Director Bristol Myers Squibb Director of Manufacturing Adaptimmune Chief Patient Supply Officer Bristol Myers Squibb Engineer ADMA Biologics VP of Quality BMS - Cell Therapy Tech Ops Sr.
    [Show full text]
  • Sangamo Biosciences Presents New Data from in Vivo Protein Replacement Platform Programs for MPS I and MPS II at the 12Th Annual Worldsymposium™ Meeting
    Sangamo Therapeutics Logo Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium™ Meeting March 2, 2016 IVPRP Approach Permits Therapeutic Enzymes for Lysosomal Storage Disorders to Cross the Blood Brain Barrier Improving Cognitive Symptoms of Disease RICHMOND, Calif., March 2, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced the presentation of new preclinical data in disease models from its In Vivo Protein Replacement Platform™ (IVPRP) programs for MPS I (Hurler syndrome) and MPS II (Hunter syndrome). The data demonstrate that the Company's IVPRP approach enabled stable production of therapeutic levels of replacement enzyme from the liver into the circulation and secondary tissues, including the brain, resulting in significant reduction in biomarkers of the disease and, importantly, statistically significant improvements in cognitive function in treated animals. The data were presented by Sangamo scientists and their collaborators at the University of Minnesota in two oral presentations at the 2016 Annual WORLDSymposium™ Meeting being held in San Diego from February 29 to March 4, 2016. "These data represent a fundamental shift in the therapeutic intervention in Hunter and Hurler syndromes. The data demonstrate that constant, stable production of both the human alpha-L-iduronidase and iduronate 2-sulfatase enzymes generated by the IVPRP strategy enables its transport from the circulation into the brain in sufficient quantities to have a therapeutic benefit on neurological aspects of the disease," said Chester Whitley, Ph.D., M.D., director of the Gene Therapy Center at the University of Minnesota Medical School.
    [Show full text]
  • Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
    Sangamo Therapeutics Logo Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results February 28, 2020 Conference Call and Webcast Scheduled for 8 a.m. Eastern Time BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights. “This quarter marked an important milestone for Sangamo, as we transitioned to a Phase 3 company following the transfer of the IND for SB-525 hemophilia A gene therapy to our partner Pfizer, who plan to commence the registrational study this year. This is a significant step in our mission to bring our genomic medicines to patients,” said Sandy Macrae, CEO of Sangamo. “Additionally this year, we look forward to progressing our wholly owned assets, ST-920 gene therapy for Fabry disease and TX200 CAR-Treg cell therapy, in the clinic, and will work closely with our collaborator, Kite, as they advance KITE-037, an anti-CD19 allogeneic CAR-T therapy into a Phase 1/2 clinical trial. We will also continue to advance new IND targets in highly prevalent diseases, as exemplified by the newly announced Biogen collaboration, and will continue to look for additional synergistic partnership opportunities to advance our mission to bring innovative genomic medicines to patients and to create value for our shareholders.” Recent Highlights Yesterday, announced global collaboration agreement with Biogen to develop and commercialize gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases. Under the terms of the collaboration, Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target.
    [Show full text]
  • Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
    Sangamo Therapeutics Logo Sangamo Therapeutics Reports Second Quarter 2019 Financial Results August 7, 2019 Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 7, 2019-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights. “We continue to progress our strategy to develop our diversified portfolio of genomic medicine product candidates using our expertise in gene therapy, cell therapy, genome editing and gene regulation,” said Sandy Macrae, CEO of Sangamo. “Last month, we reported updated results for SB-525, our investigational gene therapy for hemophilia A. We are pleased with the emerging clinical profile and competitive positioning of SB-525 and are preparing for a Phase 3 registrational study with our partner Pfizer. The THALES study evaluating ST-400, a gene-edited cell therapy for beta thalassemia being developed with Sanofi, is progressing well and recently enrolled a fourth patient. In the upcoming months, two of our wholly owned programs, ST-920, an investigational gene therapy for Fabry disease, and TX-200, our first CAR-Treg product candidate, are also expected to advance into the clinic.” “We have observed significant increases in efficacy above a defined vector dose threshold with AAV6, the vector we use in our hemophilia gene therapy and our in vivo genome editing clinical programs,” Dr. Macrae continued. “These recent insights into the kinetics of AAV6 suggest rational methods for improving the delivery of zinc finger nucleases, which we believe may substantially enhance the efficacy of in vivo genome editing, especially when added to the significantly increased potency that we expect to obtain with our updated gene editing reagents.
    [Show full text]
  • Sangamo Therapeutics Announces Presentations at 2019 Annual Meeting of the American Society of Gene & Cell Therapy
    Sangamo Therapeutics Logo Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy April 15, 2019 BRISBANE, Calif., April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that Sangamo scientists and collaborators will present data from the Company's clinical and preclinical pipeline at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held April 29th to May 2nd, 2019 in Washington, D.C. Abstracts accepted for presentation highlight data from the Company's gene therapy program in Fabry disease; ex vivo gene-edited cell therapy programs in hemoglobinopathies being developed in partnership with Sanofi; and preclinical programs for CNS diseases using Sangamo's gene regulation approach, which include tauopathies, C9ORF72-linked ALS in collaboration with Pfizer, and Huntington's disease in collaboration with Takeda. "Sangamo's strong scientific presence at ASGCT demonstrates the breadth of our therapeutic pipeline and our expertise in innovative genomic medicines research and development," said Adrian Woolfson, M.D., Ph.D., Sangamo's Executive Vice President of Research and Development. "Through our pioneering work in developing zinc fingers for ex vivo and in vivo genome editing, we've gained invaluable insights into AAV manufacturing and delivery, as well as gene editing precision, efficiency, and specificity. We're now applying these insights to our integrated portfolio of programs in
    [Show full text]
  • Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
    Sangamo Therapeutics Logo Sangamo Therapeutics Reports Third Quarter 2019 Financial Results November 6, 2019 Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 6, 2019-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights. “We continue to prioritize and progress our clinical development programs, as demonstrated by the accepted ASH poster presentations for our two most advanced programs, SB-525 hemophilia A gene therapy and ST-400 beta thalassemia cell therapy. Patients are currently being screened for enrollment into the clinical study evaluating ST-920, our wholly owned Fabry disease gene therapy, and we expect to enroll a first patient by the end of the year. We have also recently submitted a CTA for the clinical trial of our CAR-Treg, TX200, in mismatched renal transplantation,” said Sandy Macrae, CEO of Sangamo. “As it is important that we continue to articulate our drug development, research, and partnership strategies, we will host a Sangamo R&D day in New York on December 17, 2019. At this meeting, we will provide updates across our various genomic medicine programs, offer our perspective on the clinical data at ASH, share improvements across our technology platforms, and provide an overview of the manufacturing strategy to support our clinical and commercial supply.” Recent Highlights Clinical Earlier today, announced the upcoming poster presentation of three abstracts at the 61st American Society of Hematology (ASH) annual meeting in Florida: Updated follow-up of the Phase 1/2 Alta Study assessing SB-525 gene therapy in adult patients with severe hemophilia A in partnership with Pfizer.
    [Show full text]
  • Sangamo Announces Publication in Molecular Therapy of Preclinical Study Data from MPS II in Vivo Genome Editing Program
    Sangamo Therapeutics Logo Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program April 4, 2018 Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial RICHMOND, Calif., April 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today the publication of preclinical murine study data from the company's in vivo genome editing program for Mucopolysaccharidosis Type II (MPS II) in the April 2018 issue of Molecular Therapy. In the study, in a mouse model of MPS II, zinc finger nuclease (ZFN)-mediated genome editing of cells in the liver resulted in expression of therapeutic levels of iduronate 2-sulfatase (IDS), an enzyme MPS II patients lack, and in the prevention of metabolic and neurological disease symptoms. The work was conducted in collaboration with the University of Minnesota's Center for Genome Engineering. The preclinical study provided proof of concept for development of SB-913, an in vivo genome editing product candidate Sangamo is currently evaluating in the CHAMPIONS Study, a Phase 1/2 clinical trial assessing the potential safety and efficacy of SB-913 in up to nine adult males with attenuated MPS II. SB-913 uses Sangamo's ZFN genome editing technology delivered intravenously via AAV6 vectors and is a single-treatment strategy intended to provide stable, continuous production of the IDS enzyme. About the Preclinical Study Male MPS II model mice between six and nine weeks of age were injected with one of three increasing dose levels of a genome editing treatment consisting of AAV2/8 vectors encoding a pair of ZFNs and a corrective human IDS (hIDS) gene.
    [Show full text]
  • Sangamo Announces Upcoming Clinical Data Presentations at Worldsymposium 2019
    Sangamo Therapeutics Logo Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019 January 4, 2019 RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that interim clinical data from the Company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida. The WORLDSymposium program includes two platform presentations from clinical trials of Sangamo's zinc finger nuclease (ZFN)-mediated in vivo genome editing product candidates, SB-318 and SB-913, which are being evaluated for the treatment of mucopolysaccharidosis type I (MPS I) and type II (MPS II), respectively: "CHAMPIONS: A Phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)" Presenter: Joseph Muenzer, M.D., Ph.D., University of North Carolina School of Medicine February 7th, 2019 at 11:00 a.m. Eastern Time "EMPOWERS: A Phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler Syndrome)" Presenter: Paul Harmatz, MD, UCSF Benioff Children's Hospital Oakland February 7th, 2019 at 11:15 a.m. Eastern Time The SB-913 (MPS II) presentation is expected to include interim data on safety and biochemical measurements at up to 24 weeks from six subjects enrolled in the three dose cohorts of the CHAMPIONS Study. The SB-318 (MPS I) presentation is expected to describe the scientific rationale for SB-318, the clinical trial design, and preliminary safety and biochemical measurements at up to four weeks from the first three patients enrolled in the EMPOWERS Study.
    [Show full text]